# Patrick Hsu

> Patrick Hsu is a seed investor at NFDG Ventures backing Health Care. See 6 investments, round sizes, portfolio and contact details. Updated Oct 2026.

- Type: Angel Investor
- Fund: [NFDG Ventures](https://shizune.co/investors/profile/nfdg-ventures)
- Location: Cambridge, United States
- Total investments: 6
- Last investment: Jun 2025
- Lead investor: 0%
- Last updated: Oct 2026
- LinkedIn: https://www.linkedin.com/in/pdhsu/
- X (Twitter): https://twitter.com/pdhsu

Patrick Hsu is a seed investor at NFDG Ventures in Cambridge focused on Health Care and Biotechnology. Patrick Hsu

## Contacts

5 contacts available for Patrick Hsu: work email, personal email, work phone, personal phone and socials. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-email/patrick-hsu-77d9?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 2 | 33% |
| Biotechnology | 2 | 33% |
| Medical | 1 | 17% |
| Software | 1 | 17% |
| Clinical Trials | 1 | 17% |

7 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 2 | 33% |
| Series A | 1 | 17% |
| Series B | 1 | 17% |

## Investments

| Company | Description | Round size | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Traversal | Traversal is building the AI SRE for the enterprise. | $48M | Series A | Jun 18, 2025 | https://www.traversal.com/ |
| Kerna Labs | Developing better genetic medicines, built with AI. |  | Seed | Jan 13, 2025 | http://kernalabs.ai |
| Vial | Vial was founded to execute on a mission to reimagine clinical trials by delivering faster and more efficient trials for sponsors. Vial’s powerful technology platform delivers faster, more efficient trials that are up to 50% cheaper. | $67M | Series B | Nov 30, 2022 | https://vial.com |
| Nucleus | Nucleus provides genetic analysis of greater breadth, depth, and beauty. Users can upload their genetic information obtained through an established company. The proprietary algorithms will calculate polygenic risk scores and measure disease risk based on analysis of genetic variants and display them in a user-friendly platform. | $14M | Seed | Jul 14, 2022 |  |
| Nucleus | Nucleus provides genetic analysis of greater breadth, depth, and beauty. Users can upload their genetic information obtained through an established company. The proprietary algorithms will calculate polygenic risk scores and measure disease risk based on analysis of genetic variants and display them in a user-friendly platform. | $3.5M | Seed | Dec 15, 2021 |  |

5 of 6 investments shown.

## Co-investors
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund, 3 deals together
- [Hanabi Capital](https://shizune.co/investors/profile/hanabi-capital) — VC Fund, 3 deals together
- [Shrug Capital](https://shizune.co/investors/profile/shrug-capital) — VC Fund, 3 deals together
- [Founders Fund](https://shizune.co/investors/profile/founders-fund) — VC Fund, 2 deals together
- [Kleiner Perkins](https://shizune.co/investors/profile/kleiner-perkins-caufield-byers) — VC Fund, 2 deals together
- [Night Ventures](https://shizune.co/investors/profile/night-ventures) — VC Fund, 2 deals together

## About NFDG Ventures

VC Fund · San Francisco, United States

NFDG Ventures is a venture capital firm of Nat Friedman and Daniel Gross.

4 contacts available at NFDG Ventures.

| Name | Title | Profile |
| --- | --- | --- |
| Leonard Bogdonoff | Investor | https://shizune.co/investors/profile/leonard-bogdonoff |
| Nat Friedman | Founder and Managing Partner | https://shizune.co/investors/profile/nat-friedman-5a2d |
| Nat Friedman | Founder and Managing Partner | https://shizune.co/investors/profile/nat-friedman |
| Nat Friedman | Founder and Managing Partner | https://shizune.co/investors/profile/knut-friedman |

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund

### Similar country
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund
- [SV Angel](https://shizune.co/investors/profile/sv-angel) — VC Fund

## Featured in investor lists
- [Biotech Angel Investors in United States](https://shizune.co/investors/biotech-angel-investors-united-states)

## FAQ

### What does Patrick Hsu invest in?

Patrick Hsu invests primarily in Health Care, Biotechnology and Medical startups, most often at Seed and Series A stage. Most of the 6 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Patrick Hsu?

Public channels for Patrick Hsu include LinkedIn and X (Twitter). For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### When did Patrick Hsu last invest?

The most recent investment recorded for Patrick Hsu closed in Jun 2025. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co